Clinical Trial Details
| Trial ID: | L2085 |
| Source ID: | NCT05307731 |
| Associated Drug: | Fingolimod |
| Title: | Fingolimod for Type 2 Diabetes Mellitus |
| Acronym: | |
| Status: | RECRUITING |
| Study Results: | NO |
| Results: | |
| Conditions: | Diabetes Mellitus, Type 2 |
| Interventions: | DRUG: Fingolimod|DRUG: guideline-based treatment for DM |
| Outcome Measures: | Primary: The changes of glycosylated hemoglobin, compared with baseline, 180 days | Secondary: The changes of glycosylated hemoglobin, compared with baseline, 90 days, 120 days|The changes of treatment drugs, compared with baseline, including drug numbers and doses, 90 days, 120 days, 180 days|The changes of 2-hour postprandial blood glucose, compared with baseline, 30 days, 90 days, 120 days, 180 days|The changes of fasting blood glucose, compared with baseline, 30 days, 90 days, 120 days, 180 days|Beta cell function, compared with baseline, an oral glucose tolerance tests(OGTT) will be used to assess beta cell function., 30 days, 90 days, 120 days, 180 days|The changes of insulin, compared with baseline, 30 days, 90 days, 120 days, 180 days|The changes of C-peptide, compared with baseline, 30 days, 90 days, 120 days, 180 days|any adverse events, 180 days |
| Sponsor/Collaborators: | Sponsor: General Hospital of Shenyang Military Region |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE4 |
| Enrollment: | 40 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2022-03-15 |
| Completion Date: | 2025-03-15 |
| Results First Posted: | |
| Last Update Posted: | 2024-07-30 |
| Locations: | Department of Neurology, General Hospital of Northern Theater Command, Shenyang, 110016, China |
| URL: | https://clinicaltrials.gov/show/NCT05307731 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|